Gilead Sciences Shares Outstanding 2006-2019 | GILD

Gilead Sciences shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Gilead Sciences shares outstanding for the quarter ending March 31, 2019 were 1.283B, a 2.8% decline year-over-year.
Gilead Sciences 2018 shares outstanding were 1.308B, a 0.83% decline from 2017.
Gilead Sciences 2017 shares outstanding were 1.319B, a 2.87% decline from 2016.
Gilead Sciences 2016 shares outstanding were 1.358B, a 10.72% decline from 2015.

Gilead Sciences Annual Shares Outstanding (Millions of Shares)
2018	1,308
2017	1,319
2016	1,358
2015	1,521
2014	1,647
2013	1,695
2012	1,583
2011	1,580
2010	1,747
2009	1,868
2008	1,918
2007	1,929
2006	1,836
2005	1,897

Gilead Sciences Quarterly Shares Outstanding (Millions of Shares)
Q1 2019	1,283
Q4 2018	1,308
Q3 2018	1,307
Q2 2018	1,308
Q1 2018	1,320
Q4 2017	1,319
Q3 2017	1,319
Q2 2017	1,317
Q1 2017	1,320
Q4 2016	1,358
Q3 2016	1,339
Q2 2016	1,355
Q1 2016	1,412
Q4 2015	1,521
Q3 2015	1,503
Q2 2015	1,540
Q1 2015	1,569
Q4 2014	1,647
Q3 2014	1,637
Q2 2014	1,664
Q1 2014	1,680
Q4 2013	1,695
Q3 2013	1,692
Q2 2013	1,695
Q1 2013	1,665
Q4 2012	1,583
Q3 2012	1,585
Q2 2012	1,561
Q1 2012	1,555
Q4 2011	1,580
Q3 2011	1,563
Q2 2011	1,602
Q1 2011	1,624
Q4 2010	1,747
Q3 2010	1,694
Q2 2010	1,798
Q1 2010	1,857
Q4 2009	1,868
Q3 2009	1,865
Q2 2009	1,869
Q1 2009	1,885
Q4 2008	1,918
Q3 2008	1,921
Q2 2008	1,931
Q1 2008	1,933
Q4 2007	1,929
Q3 2007	1,918
Q2 2007	1,936
Q1 2007	1,925
Q4 2006	1,836
Q3 2006	1,830
Q2 2006	1,905
Q1 2006	1,927
Q4 2005	1,897
Q3 2005	1,904
Q2 2005	1,890
Q1 2005	1,870

Sector	Industry	Market Cap	Revenue
Medical	Medical - Biomedical and Genetics	$82.919B	$22.127B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Stock Name	Country	Market Cap	PE Ratio
Amgen (AMGN)	United States	$108.806B	12.30
Celgene (CELG)	United States	$63.614B	10.78
Biogen (BIIB)	United States	$44.842B	8.51
Vertex Pharmaceuticals (VRTX)	United States	$44.598B	53.91
Illumina (ILMN)	United States	$43.100B	49.95
CSL (CSLLY)	Australia	$35.794B	0.00
Regeneron Pharmaceuticals (REGN)	United States	$32.576B	15.31
Actelion (ALIOF)	Switzerland	$29.891B	0.00
Alexion Pharmaceuticals (ALXN)	United States	$27.088B	15.33
Incyte (INCY)	United States	$17.271B	70.03
Exact Sciences (EXAS)	United States	$14.835B	0.00
BioMarin Pharmaceutical (BMRN)	United States	$14.607B	0.00
SINO PHARMACEUT (SBMFF)	China	$14.154B	0.00
Seattle Genetics (SGEN)	United States	$12.140B	0.00
Sarepta Therapeutics (SRPT)	United States	$11.068B	0.00
Genmab (GNMSF)	Denmark	$11.046B	56.15
Array BioPharma (ARRY)	United States	$10.373B	0.00
Galapagos (GLPG)	Belgium	$9.397B	0.00
Bio-Rad Laboratories (BIO.B)	United States	$9.283B	49.21
QIAGEN (QGEN)	Netherlands	$8.917B	29.29
Guardant Health (GH)	United States	$8.158B	0.00
Alnylam Pharmaceuticals (ALNY)	United States	$8.030B	0.00
Bio-Techne Corp (TECH)	United States	$7.933B	54.13
Bluebird Bio (BLUE)	United States	$7.614B	0.00
Exelixis (EXEL)	United States	$6.419B	16.36
Amarin (AMRN)	Ireland	$5.979B	0.00
BeiGene (BGNE)	Cayman Islands	$5.801B	0.00
Ascendis Pharma (ASND)	Denmark	$4.841B	0.00
Blueprint Medicines (BPMC)	United States	$4.775B	0.00
ARGENX SE-ADR (ARGX)	Netherlands	$4.762B	0.00
Moderna (MRNA)	United States	$4.642B	0.00
Horizon Pharma Public (HZNP)	Ireland	$4.456B	11.48
Repligen (RGEN)	United States	$4.099B	102.12
Mirati Therapeutics (MRTX)	United States	$3.821B	0.00
Spark Therapeutics (ONCE)	United States	$3.720B	0.00
ACADIA Pharmaceuticals (ACAD)	United States	$3.705B	0.00
China Biologic Products (CBPO)	China	$3.661B	23.25
Alkermes (ALKS)	Ireland	$3.651B	0.00
Ultragenyx Pharmaceutical (RARE)	United States	$3.569B	0.00
MorphoSys AG (MOR)	Germany	$3.528B	0.00
Arena Pharmaceuticals (ARNA)	United States	$3.064B	6.23
Amicus Therapeutics (FOLD)	United States	$2.934B	0.00
Immunomedics (IMMU)	United States	$2.860B	0.00
UniQure (QURE)	Netherlands	$2.736B	0.00
Medicines (MDCO)	United States	$2.670B	0.00
Reata Pharmaceuticals (RETA)	United States	$2.620B	0.00
CRISPR Therapeutics AG (CRSP)	Switzerland	$2.595B	0.00
MyoKardia (MYOK)	United States	$2.466B	0.00
Halozyme Therapeutics (HALO)	United States	$2.370B	0.00
Nabriva Therapeutics AG (NBRV)	Ireland	$2.357B	0.00
NeoGenomics (NEO)	United States	$2.277B	149.06
Emergent Biosolutions (EBS)	United States	$2.269B	19.71
Ligand Pharmaceuticals (LGND)	United States	$2.233B	18.49
Acceleron Pharma (XLRN)	United States	$2.230B	0.00
Myriad Genetics (MYGN)	United States	$2.092B	20.81
Genomic Health (GHDX)	United States	$2.075B	44.07
Zai Lab (ZLAB)	China	$2.068B	0.00
Intercept Pharmaceuticals (ICPT)	United States	$2.045B	0.00
Akcea Therapeutics (AKCA)	United States	$2.041B	0.00
Denali Therapeutics (DNLI)	United States	$1.988B	0.00
REGENXBIO (RGNX)	United States	$1.800B	0.00
Insmed (INSM)	United States	$1.720B	0.00
Cambrex (CBM)	United States	$1.514B	19.14
AnaptysBio (ANAB)	United States	$1.474B	0.00
RA PHARMCTL INC (RARX)	United States	$1.418B	0.00
Fate Therapeutics (FATE)	United States	$1.393B	0.00
Innoviva (INVA)	United States	$1.361B	3.76
Sangamo Therapeutics (SGMO)	United States	$1.338B	0.00
Alector (ALEC)	United States	$1.298B	0.00
Athenex (ATNX)	United States	$1.278B	0.00
Coherus BioSciences (CHRS)	United States	$1.226B	0.00
Orchard Therapeutics (ORTX)	United Kingdom	$1.185B	0.00
Editas Medicine (EDIT)	United States	$1.174B	0.00
Epizyme (EPZM)	United States	$1.156B	0.00
Dicerna Pharmaceuticals (DRNA)	United States	$1.032B	0.00
Cara Therapeutics (CARA)	United States	$1.030B	0.00
Codexis (CDXS)	United States	$1.011B	0.00
Twist Bioscience (TWST)	United States	$0.982B	0.00
ANI Pharmaceuticals (ANIP)	United States	$0.973B	17.25
Zymeworks (ZYME)	Canada	$0.952B	0.00
Momenta Pharmaceuticals (MNTA)	United States	$0.947B	0.00
Principia Biopharma (PRNB)	United States	$0.921B	0.00
Adverum Biotechnologies (ADVM)	United States	$0.891B	0.00
ZIOPHARM Oncology Inc (ZIOP)	United States	$0.884B	0.00
Retrophin (RTRX)	United States	$0.879B	0.00
BAVARIAN NORDIC (BVNRY)	Denmark	$0.856B	0.00
Vericel (VCEL)	United States	$0.822B	0.00
Alder BioPharmaceuticals (ALDR)	United States	$0.820B	0.00
WAVE Life Sciences (WVE)	Singapore	$0.794B	0.00
Arvinas (ARVN)	United States	$0.789B	0.00
Intellia Therapeutics (NTLA)	United States	$0.782B	0.00
Precision BioSciences (DTIL)	United States	$0.701B	0.00
Zealand Pharma (ZEAL)	Denmark	$0.692B	8.08
Vanda Pharmaceuticals (VNDA)	United States	$0.688B	32.47
Zealand Pharma (ZLDPF)	Denmark	$0.683B	0.00
Intra-Cellular Therapies (ITCI)	United States	$0.652B	0.00
Cytokineticsorporated (CYTK)	United States	$0.643B	0.00
Cellectis S.A (CLLS)	France	$0.634B	0.00
Heska (HSKA)	United States	$0.622B	63.66
Autolus Therapeutics (AUTL)	United Kingdom	$0.612B	0.00
DBV Technologies S.A (DBVT)	France	$0.600B	0.00
Stemline Therapeutics (STML)	United States	$0.588B	0.00
Clovis Oncology (CLVS)	United States	$0.580B	0.00
Anika Therapeutics (ANIK)	United States	$0.577B	19.72
Lexicon Pharmaceuticals (LXRX)	United States	$0.561B	0.00
OXFORD BIOMEDCL (OXBDF)	United Kingdom	$0.560B	0.00
Revance Therapeutics (RVNC)	United States	$0.554B	0.00
CytomX Therapeutics (CTMX)	United States	$0.527B	0.00
Pharming Group (PHGUF)	Netherlands	$0.521B	0.00
MiMedx (MDXG)	United States	$0.503B	0.00
Mesoblast (MESO)	Australia	$0.494B	0.00
PHARMA MAR SA (PHMMF)	Spain	$0.452B	0.00
UROGEN PHARMA (URGN)	United States	$0.438B	0.00
Basilea Pharmaceutica AG (BPMUF)	Switzerland	$0.437B	0.00
Puma Biotechnology (PBYI)	United States	$0.394B	0.00
Prothena (PRTA)	Ireland	$0.393B	0.00
AC Immune SA (ACIU)	Switzerland	$0.378B	24.35
PDL BioPharma (PDLI)	United States	$0.376B	8.97
Biofrontera AG (BFRA)	Germany	$0.373B	0.00
Sinovac Biotech (SVA)	China	$0.371B	0.00
Arcus Biosciences (RCUS)	United States	$0.364B	0.00
Gritstone Oncology (GRTS)	United States	$0.361B	0.00
Starpharma Holdings (SPHRY)	Australia	$0.360B	0.00
Bellus Health (BLUSF)	Canada	$0.358B	0.00
Scholar Rock Holding (SRRK)	United States	$0.345B	0.00
Avid Bioservices (CDMO)	United States	$0.343B	0.00
Adaptimmune Therapeutics (ADAP)	United Kingdom	$0.342B	0.00
Merus (MRUS)	Netherlands	$0.341B	0.00
BioDelivery Sciences (BDSI)	United States	$0.341B	0.00
Albireo Pharma (ALBO)	United States	$0.340B	0.00
Acorda Therapeutics (ACOR)	United States	$0.332B	5.85
Agenus (AGEN)	United States	$0.330B	0.00
Achillion Pharmaceuticals (ACHN)	United States	$0.330B	0.00
Prometic Life Sciences (PFSCD)	Canada	$0.322B	0.00
Kadmon Holdings (KDMN)	United States	$0.321B	0.00
Theratechnologies (THERF)	Canada	$0.320B	0.00
Sorrento Therapeutics (SRNE)	United States	$0.319B	0.00
Syros Pharmaceuticals (SYRS)	United States	$0.314B	0.00
Protagonist Therapeutics (PTGX)	United States	$0.307B	0.00
Senesco Technologies (ELOX)	United States	$0.297B	0.00
AMAG Pharmaceuticals (AMAG)	United States	$0.295B	0.00
Cellular Biomedicine (CBMG)	United States	$0.277B	0.00
Inovio Pharmaceuticals (INO)	United States	$0.274B	0.00
Kindred Biosciences (KIN)	United States	$0.264B	0.00
Xenon Pharmaceuticals (XENE)	Canada	$0.258B	0.00
Sutro Biopharma (STRO)	United States	$0.256B	0.00
Syndax Pharmaceuticals (SNDX)	United States	$0.246B	0.00
PHASEBIO PHARMA (PHAS)	United States	$0.246B	0.00
ChromaDex (CDXC)	United States	$0.245B	0.00
Kamada (KMDA)	Israel	$0.239B	9.28
Dynavax Technologies (DVAX)	United States	$0.238B	0.00
Geron (GERN)	United States	$0.229B	0.00
Pieris Pharmaceuticals (PIRS)	United States	$0.225B	0.00
ADMA Biologics Inc (ADMA)	United States	$0.224B	0.00
Cel-Sci (CVM)	United States	$0.221B	0.00
CorMedix Inc (CRMD)	United States	$0.216B	0.00
Palatin Technologies (PTN)	United States	$0.215B	0.00
Athersys (ATHX)	United States	$0.213B	0.00
Aeglea BioTherapeutics (AGLE)	United States	$0.202B	0.00
Five Prime Therapeutics (FPRX)	United States	$0.202B	0.00
MannKind (MNKD)	United States	$0.201B	0.00
Mersana Therapeutics (MRSN)	United States	$0.200B	0.00
Cerecor (CERC)	United States	$0.197B	0.00
Affimed (AFMD)	Germany	$0.193B	0.00
Pfenex (PFNX)	United States	$0.187B	0.00
OSMOTICA PHARM (OSMT)	United States	$0.184B	0.00
POXEL SA FRANCE (PXXLF)		$0.184B	0.00
Abeona Therapeutics (ABEO)	United States	$0.184B	0.00
Synlogic (SYBX)	United States	$0.179B	0.00
Enzo Biochem (ENZ)	United States	$0.174B	0.00
Spero Therapeutics (SPRO)	United States	$0.174B	0.00
Compugen (CGEN)	Israel	$0.172B	0.00
Arsanis (XFOR)	United States	$0.168B	0.00
Newron Pharmaceuticals SpA (NWPHF)		$0.165B	0.00
XOMA (XOMA)	United States	$0.165B	0.00
BioTime (BTX)	United States	$0.165B	11.00
Nicox SA (NICXF)	France	$0.161B	0.00
Cue Biopharma (CUE)	United States	$0.157B	0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT)	United States	$0.156B	0.00
Strongbridge Biopharma (SBBP)	United States	$0.150B	8.66
Liquidia Technologies (LQDA)	United States	$0.144B	0.00
Celyad SA (CYAD)	Belgium	$0.142B	0.00
Alcobra (ARCT)	United States	$0.141B	0.00
OvaScience (MLND)	United States	$0.141B	0.00
Adocia (ADOCY)	France	$0.140B	0.00
Dyadic (DYAI)	United States	$0.136B	0.00
TOCAGEN INC (TOCA)	United States	$0.135B	0.00
Northwest Biotherapeutics (NWBO)	United States	$0.130B	0.00
Seres Therapeutics (MCRB)	United States	$0.127B	0.00
Aptinyx (APTX)	United States	$0.125B	0.00
NantKwest (NK)	United States	$0.121B	0.00
AVEO Pharmaceuticals (AVEO)	United States	$0.114B	0.00
Aduro Biotech (ADRO)	United States	$0.114B	0.00
Nymox Pharmaceutical (NYMX)	Canada	$0.110B	0.00
Novavax (NVAX)	United States	$0.108B	0.00
Paratek Pharmaceuticals (PRTK)	United States	$0.108B	0.00
Verastem (VSTM)	United States	$0.106B	0.00
Checkpoint Therapeutics (CKPT)	United States	$0.104B	0.00
Menlo Therapeutics (MNLO)	United States	$0.103B	0.00
ASLAN Pharmaceuticals (ASLN)	Singapore	$0.103B	0.00
Catalyst Biosciences (CBIO)	United States	$0.099B	0.00
Arbutus Biopharma (ABUS)	Canada	$0.098B	0.00
SESEN BIO, INC (SESN)	United States	$0.098B	0.00
Trevena (TRVN)	United States	$0.094B	0.00
Fortress Biotech (FBIO)	United States	$0.089B	0.00
Pluristem Therapeutics (PSTI)	Israel	$0.088B	0.00
ANIXA BIOSCIENCES INC (ANIX)	United States	$0.087B	0.00
Spring Bank Pharmaceuticals (SBPH)	United States	$0.084B	0.00
Catabasis Pharmaceuticals (CATB)	United States	$0.082B	0.00
Aridis Pharmaceuticals (ARDS)	United States	$0.080B	0.00
Unum Therapeutics (UMRX)	United States	$0.079B	0.00
VBI Vaccines (VBIV)	United States	$0.079B	0.00
AquaBounty Technologies (AQB)	United States	$0.078B	0.00
Curis (CRIS)	United States	$0.076B	0.00
Selecta Biosciences (SELB)	United States	$0.076B	0.00
Merrimack Pharmaceuticals (MACK)	United States	$0.071B	0.00
Idera Pharmaceuticals (IDRA)	United States	$0.071B	0.00
Applied Genetic Technologies (AGTC)	United States	$0.071B	38.80
VTv Therapeutics (VTVT)	United States	$0.070B	0.00
Signal Genetics (MGEN)	United States	$0.070B	0.00
Orgenesis (ORGS)	United States	$0.067B	0.00
Oncobiologics (OTLK)	United States	$0.064B	0.00
Alimera Sciences (ALIM)	United States	$0.062B	0.00
Antibe Therapeutics (ATBPF)	Canada	$0.061B	0.00
ARAVIVE, INC (ARAV)	United States	$0.060B	0.00
NewLink Genetics (NLNK)	United States	$0.060B	0.00
Organovo Holdings (ONVO)	United States	$0.060B	0.00
Sunesis Pharmaceuticals (SNSS)	United States	$0.058B	0.00
Protalix BioTherapeutics (PLX)	Israel	$0.058B	0.00
Prima BioMed (IMMP)	Australia	$0.057B	0.00